logo
  

Stock Alert: Immuron Shares Soar 76% In Early Trade

Shares of Immuron Ltd. (IMRN) are rallying over 76% in pre-market today, after the company announced that the Naval Medical Research Center or NMRC has received written guidance from the U.S. FDA in relation to the clinical development pathway of a new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli or ETEC infections.

Highlights:

* Two human phase II clinical trials to be conducted in 2021.
* One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis.
* The second trial will focus on ETEC infections.

The stock has been trading in the range of $1.55 - $28.99 for the past one year, and closed Friday's trade at $6.37, up 22 cents or 3.58%. IMRN is currently trading at $11.25, up $4.88 or 76.61% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT